Protherics PLC (“Protherics” or the " Company”), the international biopharmaceutical company focused on critical care and oncology, today announces that it has signed an agreement with CoVaccine BV (“CoVaccine”), a Dutch company, to acquire CoVaccine’s novel adjuvant. The adjuvant has been selected by Protherics for inclusion in its Angiotensin Vaccine, for the treatment of hypertension, following screening of a number of third party proprietary adjuvants.
